tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: Oculis Holding (OCS), Natera (NTRA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oculis Holding (OCSResearch Report), Natera (NTRAResearch Report) and Disc Medicine (IRONResearch Report) with bullish sentiments.

Oculis Holding (OCS)

In a report issued on May 9, Colleen M. Kusy from Robert W. Baird reiterated a Buy rating on Oculis Holding, with a price target of $35.00. The company’s shares closed last Monday at $12.07.

According to TipRanks.com, Kusy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.1% and a 33.5% success rate. Kusy covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Iovance Biotherapeutics, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Oculis Holding is a Strong Buy with an average price target of $27.00, implying a 123.1% upside from current levels. In a report issued on May 9, Leerink Partners also maintained a Buy rating on the stock with a $22.00 price target.

See today’s best-performing stocks on TipRanks >>

Natera (NTRA)

Leerink Partners analyst Puneet Souda maintained a Buy rating on Natera on May 9 and set a price target of $130.00. The company’s shares closed last Monday at $103.33, close to its 52-week high of $108.32.

According to TipRanks.com, Souda is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.3% and a 37.3% success rate. Souda covers the Healthcare sector, focusing on stocks such as Sonida Senior Living, Inc., AbCellera Biologics, and Castle Biosciences.

Natera has an analyst consensus of Strong Buy, with a price target consensus of $112.31, representing a 6.9% upside. In a report issued on May 10, Canaccord Genuity also maintained a Buy rating on the stock with a $130.00 price target.

Disc Medicine (IRON)

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Disc Medicine on May 9 and set a price target of $65.00. The company’s shares closed last Monday at $31.01, close to its 52-week low of $25.60.

According to TipRanks.com, Smith is a top 100 analyst with an average return of 35.1% and a 44.3% success rate. Smith covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, MoonLake Immunotherapeutics, and Connect Biopharma Holdings.

Disc Medicine has an analyst consensus of Strong Buy, with a price target consensus of $53.88, which is a 74.9% upside from current levels. In a report issued on May 9, BMO Capital also maintained a Buy rating on the stock with a $50.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OCS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles